lactam bridge is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-12-03. Numbers and descriptions here follow the published literature rather than marketing material.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.
Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Alpha-MSH analogue with a lactam ring |
| Molecular formula | C50H69N15O9 | Commonly cited value for the neutral peptide |
| Molecular weight | 1024.18 g/mol | Calculated for the free molecule |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility | Soluble in water, DMSO and ethanol | Dissolution in pure water is often slow |
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
In the Cannabis plant, THC occurs mainly as tetrahydrocannabinolic acid (THCA, 2-COOH-THC). Geranyl pyrophosphate and olivetolic acid react, catalysed by an enzyme to produce cannabigerolic acid, which is cyclized by the enzyme THC acid synthase to give THCA. Over time, or when heated, THCA is decarboxylated, producing THC. The pathway for THCA biosynthesis is similar to that which produces the bitter acid humulone in hops. It can also be produced in genetically modified yeast.
Scott Tanner is a Canadian scientist, inventor, and entrepreneur. His areas of expertise include mass spectroscopy, especially inductively coupled plasma mass spectrometry (ICP-MS), and mass cytometry. Tanner is best known for his work on the fundamentals of inductively coupled plasma mass spectrometry, for the invention of mass cytometry, and co-founding (with Dmitry Bandura, Vladimir Baranov and Olga Ornatsky) DVS Sciences in 2004,(acquired by Fluidigm in 2014 and then renamed to Standard BioTools in 2022) the company that first commercialized the instrument and reagents of mass cytometry.
== History == Packaging of food products has seen a vast transformation in technology usage and application from the Stone Age to the Industrial Revolution: 7000 BC: The adoption of pottery and glass, with widespread production beginning around 1500 BC. 1700s: The first manufacturing production of tinplate was introduced in England (1699) and in France (1720). Afterwards, the Dutch Navy started to use such packaging to prolong the preservation of food products. 1804: Nicolas Appert, in response to inquiries into extending the shelf life of food for the French Army, employed glass bottles with heat sterilization. Glass was later replaced by metal cans in this application. However, there has been debate about who first introduced the use of tinplates as food packaging. 1870: The use of paper board was launched, and corrugated materials were patented. 1880s: First cereal packaged in a folding box by Quaker Oats. 1890s: The crown cap for glass bottles was patented by William Painter. 1950s: The bag-in-box system was invented by American chemist William R. Scholle – initially for acid liquids, but quickly also used for food liquids. 1960s: Development of the two-piece drawn and wall-ironed metal cans in the US, along with the ring-pull opener and the Tetra Brik Aseptic carton package. 1970s: The barcode system was introduced in the retail and manufacturing industry. PET plastic blow-mold bottle technology, which is widely used in the beverage industry, was introduced. 1990s: The application of digital printing on food packages became widely adopted.
India is a megadiverse country, a term employed for 17 countries that host high biological diversity and contain many species indigenous, or endemic, to them. India is the habitat for 8.6% of all mammals, 13.7% of bird species, 7.9% of reptile species, 6% of amphibian species, 12.2% of fish species, and 6.0% of all flowering plant species. Fully a third of Indian plant species are endemic. India also overlaps four of the world's 34 biodiversity hotspots, or regions that display significant habitat loss in the presence of high endemism. India's densest forests, such as the tropical moist forest of the Andaman Islands, the Western Ghats, and Northeast India, occupy about 3% of its land area. Moderately dense forest, whose canopy density is between 40% and 70%, occupies 9.39% of India's land area. It predominates in the temperate coniferous forest of the Himalayas, the moist deciduous sal forest of eastern India, and the dry deciduous teak forest of central and southern India. India has two natural zones of thorn forest, one in the Deccan Plateau, immediately east of the Western Ghats, and the other in the western part of the Indo-Gangetic plain, now turned into rich agricultural land by irrigation, its features no longer visible. Among the Indian subcontinent's notable indigenous trees are the astringent Azadirachta indica, or neem, which is widely used in rural Indian herbal medicine, and the luxuriant Ficus religiosa, or peepul, which is displayed on the ancient seals of Mohenjo-daro, and under which the Buddha is recorded in the Pali canon to have sought enlightenment.
Sources: en.wikipedia.org
=== Events === Japan Tamagokake Gohan Symposium: Held annually in Unnan, Shimane since 2005, originating from the development of the local TKG soy sauce "Otamahan." The symposium discusses the history and appeal of TKG and led to October 30th being designated "Tamagokake Gohan Day." Aspam Tamagokake Gohan Fair: Held in Aomori, Aomori in 2009 at the Aomori Prefecture Tourist Center Aspam. Guinness World Record - Town Revitalization Nippon: In Pippu, Hokkaido, on August 4, 2024, a Guinness World Record was set for the "most people making tamago kake gohan simultaneously." Proposed by local junior high students to promote the town's products (Yumepirika rice, "Kappa no Kenran" eggs, Pippu green onion soy sauce), 325 participants successfully made TKG within 5 minutes.
Other methods of preservation include the storage of specimens in spirit. Such wet specimens have special value in physiological and anatomical study, apart from providing better quality of DNA for molecular studies. Freeze drying of specimens is another technique that has the advantage of preserving stomach contents and anatomy, although it tends to shrink, making it less reliable for morphometrics.
A study at Duke–NUS Medical School found that healthy muscle releases molecular signals into the bloodstream protecting against tumor growth throughout the body, that the amount of such signals declines with age, and that exercise can restore and protect the ability of aging muscles to send these signals.
== Evolution == Phylogenetic analyses suggest that DBP diverged from ancestral albumin through gene duplication events that occurred after the separation of jawless fish (cyclostomes) from jawed vertebrates approximately 450 million years ago. This timeline is supported by the apparent absence of DBP-like proteins in lampreys and hagfish, though these organisms retain vitamin D transport capability through alternative lipoprotein-mediated mechanisms. DBP is found throughout jawed vertebrates, from bony fish to mammals, suggesting its evolution coincided with the development of calcified skeletons and more sophisticated calcium homeostasis requirements.
Insulin pumps are drug delivery devices used to treat patients with type 1 and type 2 diabetes. The Minimed Paradigm REAL-Time and Continuous Glucose Monitoring (CGM) system, which received FDA clearance in 2006, uses tubing and a reservoir with rapid-acting insulin. This "infusion set" is patient-connected via a catheter to the abdomen region. The infusion set can remain in the place for three days while the pump is clip-belt worn. There is a quick-disconnect feature for the tubing. The pump delivers insulin in two modes. In basal rate mode, the delivery is continuous in small doses similar to a pancreas, for example 0.15 units per hour throughout the day. Basal rates are set to meet individual metabolic rates. In bolus mode, the delivery is programmed to be a one-time delivery prior to eating or after an unexpected high, for example 18 units spread out to several hours. This type of continuous treatment is in contrast to traditional multiple daily injections (MDI) that use slower-acting insulin. Continuous treatment reduces glucose variability. The Paradigm system consists of two basic parts: an insulin pump and an optional glucose sensor CGM worn for up to three days. The disposable sensor is subcutaneously-placed to make glucose measurements in interstitial fluid every five minutes and transmit the reading via low power radio frequency (ISM band) to the pump for realtime display.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide modelled on alpha-melanocyte-stimulating hormone. A lactam bridge links two side chains, forming a ring that stabilises the molecule against proteolysis. It belongs to the broader melanocortin peptide family.
No national medicines agency has approved melanotan-2 for clinical use. Afamelanotide, a related but distinct peptide, holds a marketing authorisation in the European Union for a rare photosensitivity disorder. Melanotan-2 itself is handled as a laboratory chemical.
Its broad activity across melanocortin receptors makes it a tool for probing pigmentation, appetite and vascular signalling. Early trials recorded skin darkening and other effects that were not the original focus of the work. Those observations generated hypotheses that later studies have examined.
No. Melanotan-2 is manufactured synthetically. The naturally occurring peptide in the same family is alpha-melanocyte-stimulating hormone, which the body produces as part of normal endocrine and neural signalling.